UBX Stock Overview
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.
Unity Biotechnology Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.59|
|52 Week High||US$4.97|
|52 Week Low||US$0.57|
|1 Month Change||-28.16%|
|3 Month Change||-49.21%|
|1 Year Change||-86.31%|
|3 Year Change||-93.75%|
|5 Year Change||n/a|
|Change since IPO||-96.43%|
Recent News & Updates
|UBX||US Biotechs||US Market|
Return vs Industry: UBX underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: UBX underperformed the US Market which returned -18.4% over the past year.
|UBX Average Weekly Movement||9.4%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: UBX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: UBX's weekly volatility (9%) has been stable over the past year.
About the Company
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.
Unity Biotechnology Fundamentals Summary
|UBX fundamental statistics|
Is UBX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|UBX income statement (TTM)|
|Cost of Revenue||US$40.94m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.92|
|Net Profit Margin||-1,335.37%|
How did UBX perform over the long term?See historical performance and comparison
Is UBX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UBX?
Other financial metrics that can be useful for relative valuation.
|What is UBX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does UBX's PS Ratio compare to its peers?
|UBX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TCON TRACON Pharmaceuticals
UBX Unity Biotechnology
Price-To-Sales vs Peers: UBX is good value based on its Price-To-Sales Ratio (8.6x) compared to the peer average (142.2x).
Price to Earnings Ratio vs Industry
How does UBX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: UBX is good value based on its Price-To-Sales Ratio (8.6x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is UBX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||8.6x|
|Fair PS Ratio||0.005x|
Price-To-Sales vs Fair Ratio: UBX is expensive based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Share Price vs Fair Value
What is the Fair Price of UBX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate UBX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate UBX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UBX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Unity Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UBX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: UBX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: UBX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: UBX is forecast to have no revenue next year.
High Growth Revenue: UBX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UBX is forecast to be unprofitable in 3 years.
Discover growth companies
How has Unity Biotechnology performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UBX is currently unprofitable.
Growing Profit Margin: UBX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UBX is unprofitable, and losses have increased over the past 5 years at a rate of 5.2% per year.
Accelerating Growth: Unable to compare UBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: UBX has a negative Return on Equity (-126.03%), as it is currently unprofitable.
Discover strong past performing companies
How is Unity Biotechnology's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: UBX's short term assets ($81.5M) exceed its short term liabilities ($17.9M).
Long Term Liabilities: UBX's short term assets ($81.5M) exceed its long term liabilities ($43.9M).
Debt to Equity History and Analysis
Debt Level: UBX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if UBX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UBX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: UBX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 8.1% each year.
Discover healthy companies
What is Unity Biotechnology current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate UBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UBX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UBX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as UBX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Anirvan Ghosh (57 yo)
Dr. Anirvan Ghosh, Ph D., serves as Chief Executive Officer and Director of Unity Biotechnology, Inc. since March 30, 2020. Dr. Ghosh had been Senior Vice President, Head of Research and Early Development...
CEO Compensation Analysis
Compensation vs Market: Anirvan's total compensation ($USD3.94M) is above average for companies of similar size in the US market ($USD749.40K).
Compensation vs Earnings: Anirvan's compensation has been consistent with company performance over the past year.
Experienced Management: UBX's management team is considered experienced (2.3 years average tenure).
Experienced Board: UBX's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.1%.
Unity Biotechnology, Inc.'s employee growth, exchange listings and data sources
- Name: Unity Biotechnology, Inc.
- Ticker: UBX
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$41.100m
- Shares outstanding: 69.17m
- Website: https://unitybiotechnology.com
Number of Employees
- Unity Biotechnology, Inc.
- 285 East Grand Avenue
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.